Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Milvexian Form A and Form B in Healthy Participants
NCT03362437Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of milvexian in thrombosis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 3 days, Area under the concentration-time curve from time zero to time of last quantifiable concentration up to 3 days and 1 more. Started Nov 2017; status: completed.
02
Drugs
milvexian
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03362437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362437.